Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 65Other hematologic neoplasm 57Sarcoma 23Myeloid 17CNS 16Breast 9Genitourinary 7Gastrointestinal 7Plasma cell 6Dermatologic 6Other solid neoplasm 4Thoracic 2Other neoplasm 2Gynecologic 2Classical hematology 2Tumor-Agnostic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mesna × Tumor-Agnostic × Clear all
NCT00924287 2015-10-28

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
1 enrolled 8 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡